Sign In
Section Navigation
Common TitleACTION
Official Title A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (abacavir 300 mg, lamivudine 150 mg, and zidovudine 300 mg) BID vs Combivir (lamivudine 150 mg and zidovudine 300 mg) BID plus atazanavir 400 mg QD in Antiretroviral Naive HIV-1 Infected Subjects over 48 Weeks
Phase Phase IV
ClinicalTrials.gov NCT00082394
Categories Treatment-Naive
Funding
IndustryGlaxo Wellcome
References
  • Kumar PN, Salvato P, Lamarca A, et al. A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). AIDS Res Ther. 2009;6:3.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.